DANIELS RONALD J 4

What Happened
Ronald J. Daniels, a director of BridgeBio Pharma, was granted two awards on June 22, 2026: 3,990 restricted stock units (RSUs) and 5,277 RSUs (reported as a derivative), for a total of 9,267 RSUs. Each RSU represents a contingent right to one share; the awards were granted at $0.00 (no cash paid). The RSUs vest in full on June 22, 2027, subject to Daniels' continued service on the board.

Key Details

• Transaction date: June 22, 2026; reported on Form 4 filed June 24, 2026 (timely).
• Grants: 3,990 RSUs (non-derivative) and 5,277 RSUs (derivative) — total 9,267 RSUs. Grant price reported $0.00.
• Vesting: All RSUs vest in full on June 22, 2027, contingent on continued board service.
• Each RSU equals a contingent right to one share of common stock (per footnote).
• Shares owned after the transaction: not disclosed in this filing.
• No cash paid and no sale or exercise occurred; this is an equity award, not an open-market purchase or sale.

Context
RSU grants are compensation/retention awards that convert to actual shares only if vesting conditions are met; they do not reflect an immediate open-market purchase or sale. Because vesting is contingent on continued board service through June 22, 2027, these awards are primarily a retention incentive rather than an immediate signal of insider buying or selling.